Recent and expected drug approvals to widen interest in wAMD market

A flourish of activity in the wet age-related macular degeneration (wAMD) market, coupled with anticipated approvals of other products - particularly biosimilars - is expected to widen interest in the AMD market among stakeholders, says analyst.

According to data and analytics firm GlobalData’s pharmaceutical analyst Vinie Varkey: "The wAMD market is on the precipice of a wave of new products. GlobalData’s Pharmaceutical Intelligence Centre (PIC) reveals that there are currently 15 products in late-stage development that are exclusively for wAMD in the seven major markets (7MM: the USA, France, Germany, Italy, Spain, the UK, and Japan).

The majority of these products fall either into the category of anti-vascular endothelial growth factor (VEGF) therapy, a drug class that is well-established for wAMD, or are biosimilars. In terms of innovation, RGX-314 from RegenxBio (Nasdaq: RGNX) and AbbVie (NYSE: ABBV) is a gene-therapy that has the potential to be used as a one-time treatment option for patients with wAMD."